TTLC 2022

Oral and Poster Abstracts

Oral and Poster Abstracts

Please click here to view the full abstracts.

  • Oral Abstracts
  • Poster Abstracts

OA01.01 - Dissecting the Clinicopathologic, Genomic, and Immunophenotypic Correlates of KRAS G12D Mutated Non-small Cell Lung Cancer - Biagio Ricciuti, USA

OA01.02 - Genomic and Immune Characteristics of BRAF Mutated Non-small Cell Lung Cancer - Fares Alsawah, USA

OA01.03 - Investigating the Efficacy of Osimertinib in Patients with Tumors Harboring the Uncommon EGFR Exon 19 Deletion, L747_A750delinsP - Michael Grant, USA

OA01.04 - Antitumor Activity of KIN-2787, a Next-Generation pan-RAF Inhibitor, in Preclinical Models of Human BRAF-alteration Driven Non-small Cell Lung Cancer (NSCLC) - Tadashi Manabe, USA

OA01.05 - Low Dose CT (LDCT) Screening is as Efficacious in Asian Female Never-Smokers as in Asian Male Ever-Smokers in Detecting Lung Cancer: A Systemic Review and Meta-analysis of Lung Cancer Studies - Shannon Zhang, USA

P01 - ART1, an Extracellular mono-ADP-ribosyltransferase Promotes Lung Cancer Growth by Triggering Immuneresistance and Is Upregulated in Response to Cellular Stress - Sumit Mukherjee, USA

P02 - Change in Mean Platelet Volume in Patients with Non-small Cell Lung Cancer Treated with First-Line Pembrolizumab Predict Survival and Risk of Developing Immune Mediated Adverse Events - Mingjia Li, USA

P03 - Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer - Adam Schoenfeld, USA

P04 - Investigation of APR-246 in Small Cell Lung Cancer - Misty Shields, USA

P05 - Activating MET Tyrosine Kinase Domain Mutations Define a Unique Molecular Subtype of Non-Small Cell Lung Cancer. - Federica Pecci, USA

P06 - Outcomes to First-Line Pembrolizumab among Elderly Patients with PD-L1-high (≥50%) Non-small-Cell Lung Cancer. - Adriana P. C. Barrichello, USA

P07 - Pembrolizumab and Weekly Low Dose Carboplatin and Paclitaxel Compared with Pembrolizumab Alone in Patients with NSCLC and Poor PS - Safoa Addo, USA

P08 - The CANVAX Cohort Study: Immunogenicity and Safety of COVID-19 Vaccines in Patients with Cancer, in the Era of Variants - Vivek Naranbhai, USA

P09 - High PD-L1 Expression at Diagnosis Is Associated with Worse Progression Free Survival in Patients With ALK¬-rearranged Non-small Cell Lung Cancer (NSCLC) on First Line ALK Tyrosine Kinase Inhibitor (TKI) Therapy - Yunan Nie, USA

P10 - EGFR-Mutant NSCLC with De Novo or Acquired Squamous Histology: Molecular Features and Clinical Outcomes - Catherine Meador, USA

P11 - Phase II Study of Lorlatinib in Patients with ROS1-Rearranged Lung Cancer with CNS Progression on Crizotinib - Jaime Schneider, USA

P12 - Clinicopathologic Characteristics of Patients with KRAS G12D-mutated NSCLC - Alissa Cooper, USA

P13 - Real-World Experience of Lurbinectedin Beyond the Second Line in Small Cell Lung Cancer - Aakash Desai, USA

P14 - Outcome and Clinicopathologic/Molecular Characteristics of NSCLC with Cutaneous, Subcutaneous And/or Muscular Metastases - Jessica Boyce, USA

P15 - Patterns of First- and Second-Line Systemic Therapy Use Among Adults with Advanced Non-Small Cell Lung Cancer in the PROSPR-Lung Consortium - Nikki Carroll, USA

P16 - Accelerating Lung Cancer Diagnosis and Molecular Profiling through Liquid Biopsy - Miguel Garcia, Canada

P17 - Dissecting the Genomic and Tumor Immune Microenvironment Determinants of Recurrence for Surgically-Resected Stage I NSCLC - Joao Victor Alessi, USA

P18 - Genomic Determinants of Brain Metastases in ALK+ Non-Small Cell Lung Cancer - Paola Ghanem, USA

P19 - Histological Transformation and Off Target Alterations are Frequent Mechanisms of Acquired Resistance for Patients with EGFR-mutant Lung Cancer Treated with First-line Osimertinib - Noura Choudhury, USA

P20 - The Impact of Molecular Driver Mutations on Brain Metastasis Risk Depends on Timing of Brain Metastasis Relative to Diagnosis - Julie Wu, USA

P21 - Co-alterations of BRAF with TP53 in BRAF V600E Non-small Cell Lung Carcinoma - Jane SY Sui, USA

P22 - Circulating Tumor DNA Dynamics in Relapsed Small Cell Lung Cancer Are Predictive of Progression-Free and Overall Survival - Christopher Cann, USA

P23 - Clinical Outcomes of Patients with Advanced EGFR-Mutated NSCLC who Received Initial Treatment with Chemotherapy Followed by EGFR TKI - Karen Yun, USA

P24 - PI4K2A is a Therapeutic Vulnerability in Mesenchymal Lung Cancer Cells - Xiaochao Tan, USA

P25 - Using Machine Learning for Multi-Omics Data to Define Vulnerabilities in a Subset of Squamous Cell Lung Cancers - Daniel Kottmann, United Kingdom

P26 - Effect of Osimertinib and Vitamin D on Murine Gut Microbial Community Structure - Lei Deng, USA

P27 - Leveraging Novel Translational Tools to Enhance Response to Trop2-targeting Antibody-Drug Conjugates - Ralph Millett, USA

P28 - Serum Proteomics Analysis as a Potential Predictive Biomarker for Survival Outcomes and Immune-related Adverse Events (irAE) in Non-Small Cell Lung Cancer (NSCLC) Receiving Immune Checkpoint Inhibitors (ICIs) - Leeseul Kim, USA

P29 - Rapid Progression of Metastatic NSCLC treated with First Line Osimertinib: An Institutional Case Series. - Bailey Fitzgerald, USA

P30 - RNA Sequencing to Characterize Pathways in EGFR-mutated Non-Small Cell Lung Cancer - Nicole Yun, USA

P31 - The Challenges of Targeted Therapy and Tumor Lineage Plasticity – A Case Report - Joel Rivera, USA

P32 - Trial in Progress: Phase II Study of Bevacizumab in Combination with Chemoimmunotherapy Followed by Maintenance Bevacizumab plus Atezolizumab in Patients with Extensive-Stage Small Cell Lung Cancer and Liver Metastases. - Kamya Sankar, USA

P33 - Combining Immunogenic Chemotherapy with anti-PD1 Checkpoint Immunotherapy for the Treatment of Non-small Cell Lung Cancer - Diane Tseng, USA

P34 - Early Utilization of Next-Generation Sequencing Identifies Pancreatic Mass as Metastatic Tumor Originating from an EGFR Mutated Lung Adenocarcinoma - Luxi Chen, USA